Drug intelligence / Profile preview

Shufeng Zhitong Capsules

Development stage: Phase 3
Lead developer: Shanghai Kaibao Pharmaceutical
Administration: Oral

Overview

Shufeng Zhitong Capsules (疏风止痛胶囊) is an oral traditional Chinese medicine (TCM) capsule formulation being developed for the prevention and treatment of migraine. It is formulated to target the TCM-defined 'cold-congealing blood-stasis with wind' syndrome. Originally acquired by Shanghai Kaibao in 2012, the drug is currently undergoing Phase III clinical trials in China, sponsored by Beijing Boshili Pharmaceutical Technology, to evaluate its efficacy and safety as a preventive treatment for adults with migraine.

Other names: Shufeng Zhitong Capsule疏风止痛胶囊

Targets

ACE2 (Angiotensin-converting enzyme 2)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)EGFR (Epidermal growth factor receptor)PIK3CA (Phosphoinositide 3-kinase alpha)Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on Shufeng Zhitong Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shufeng Zhitong Capsules.